Cetuximab (Erbitux™)

Last Updated: 03/28/17

Status: Potential NF2 Clinical Trial

Index

  • Additional Information
  • Side Effects
  • Other Uses
Other Names Erbitux™, Anti EGFR, IMC-C225
Pharmaceutical Companies Bristol Myers Squib, Merck Serono and Eli Lilly and Company
Treatment By IV
Molecular Formula C6484H10042N1732O2023S36
Drug Bank DB00002
Inhibitor Epidermal Growth Factor Receptor (EGFR) Inhibitor
Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

1. Additional Information

Due to cardiac arrest prevention, pretreatment with diphenhydramine 30-60 min. before administration is standard of care.

2. Side Effects

Common

  • Fevers
  • Chills
  • Rigors
  • Urticaria
  • Pruritis
  • Rash
  • Hypotension
  • Bronchospasm
  • Dyspnea
  • Wheezing
  • Angioedema
  • Dizziness
  • Anaphylaxis
  • Cardiac Arrest

Uncommon

  • Photosensitivity
  • Hypomagnesemia due to Magnesium Wasting
  • Pulmonary and Cardiac Toxicity

3. Other Uses

  • Head Cancer
  • Neck Cancer
  • Colorectal Cancer
What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2017